Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

RMC 035

Next Previous
Search
Drug Profile

RMC 035

Alternative Names: A1M-001; Alfa-1-Mikroglobulin - Guard Therapeutics; Alpha-1-microglobulin - Guard Therapeutics; RMC-035; ROSgard; α1-microglobulin - Guard Therapeutics

Latest Information Update: 28 Oct 2024

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator A1M Pharma AB
  • Developer Guard Therapeutics
  • Class Antihypertensives; Radioprotectives; Recombinant proteins; Urologics
  • Mechanism of Action Alpha 1 microglobulin replacements; Antioxidants; Free radical scavengers; Haemoglobin inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Preeclampsia
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Phase II Acute kidney injury
  • No development reported Preeclampsia; Radiation injuries

Most Recent Events

  • 28 Oct 2024 No recent reports of development identified for phase-I development in Acute kidney injury in Sweden (IV)
  • 26 Aug 2024 Guard Therapeutics initiates enrolment in the phaseIIb POINTER trial for Acute kidney injury (In adults, In the elderly) in Czech Republic, Germany, Spain (IV), after August 2024 (NCT06475274)
  • 08 Aug 2024 EMA approves clinical trial application for RMC 035 in Acute kidney injury (In adults, In the elderly) in Spain, Germany, and the Czech Republic

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top